A Drug: Eculizumab (Genetical Recombination, 300Mg 30Ml/V) Intravenous Infusion Formulation 73V, B Drug: Ravulizumab (Genetical Recombination, 1100Mg 11Ml/V) Intravenous Infusion Formulation 15V

  Address - Japan

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 102283624

  Document Type - Tender Notices

Description - Description: Tender announcementThe following items will be subject to public competitive bidding.January 27, 2025Nagahiro Minato, President of Kyoto University, National University Corporationâ—ŽProcurement agency number: 415â—ŽLocation number: 26â— ‹No. 601. Procurement detailsâ‘´ Item classification number: 4⑵ Purchase item and quantityA. Pharmaceutical product: Eculizumab (recombinant, 300mg 30mL/V) IV infusion formulation, 73VB. Pharmaceutical product: Rabulizumab (recombinant, 1100mg 11mL/V) IV infusion formulation, 15V⑶. Characteristics of procurement items: See bidding instructions.â‘·. Delivery period: April 1, 2025 to March 31, 2026⑸. Delivery location: Kyoto University Hospit

Gt Ref Id - 102283624

Deadline - Feb 11, 2025